---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-066896"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2022-06-01T23:59:59+00:00"
generated_at: "2026-06-25T05:33:22.517970+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Passage Bio CEO Bruce Goldsmith steps down; Chip Cale named interim CEO, Maxine Gowen interim Executive Chair

## Summary
- Bruce Goldsmith ceases as CEO and director May 31, 2022; will serve as non-employee advisor through Sep 1, 2022 at $50k/month.
- Goldsmith receives severance: $566,500 lump sum, COBRA for 12 months, pro-rata 2022 bonus, 100,000-share option at $1.86.
- Chip Cale (General Counsel) appointed Interim CEO and President; base salary increased $15k/month, 100,000-share option at $1.80 vesting over 12 months.
- Maxine Gowen appointed Interim Executive Chair; receives $20k/month and 40,000-share option at $1.80 vesting over 12 months.
- May 26, 2022 annual meeting: Gowen and Woiwode re-elected as Class II directors; KPMG ratified as auditor for 2022.

## SEC filing metadata
- accession: 0001104659-22-066896
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2022-06-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000110465922066896/0001104659-22-066896-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000110465922066896/tm2217427d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-066896
- JSON: https://secwatch.observer/filing/0001104659-22-066896.json
- Plain text: https://secwatch.observer/filing/0001104659-22-066896.txt

## Key facts
- Executive change
  Bruce Goldsmith departed as President and Chief Executive Officer at Passage BIO, Inc..
  - Action: ceased
  - Role: President and Chief Executive Officer
  source text: Dr. Goldsmith ceased his role as the Company’s President and Chief Executive Officer, effective May 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787297/000110465922066896/0001104659-22-066896-index.htm
- Executive change
  Edgar B. (Chip) Cale was appointed as Interim Chief Executive Officer and President at Passage BIO, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer and President
  source text: Effective as of the Transition Date, the Board appointed Edgar B. (Chip) Cale, the Company’s General Counsel and Corporate Secretary, to succeed Dr. Goldsmith as Interim Chief Executive Officer and President.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787297/000110465922066896/0001104659-22-066896-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.